*The following content is generated by AI and is for reference only.
Irbesartan is a potent and selective angiotensin II receptor blocker (ARB) widely utilized in the management of hypertension and diabetic nephropathy. Chemically known as 2-butyl-3-[2-(1H-tetrazol-5-yl)phenyl]methyl]-4-methyl-6,7-dihydro-5H-furanone, its molecular formula is C₂₅H₂₈N₆O. The compound is identified by the CAS Registry Number 138402-09-8. Irbesartan functions by specifically blocking the binding of angiotensin II to the AT1 receptors found in vascular smooth muscle cells and the adrenal cortex. By inhibiting this interaction, it prevents vasoconstriction and aldosterone secretion, leading to reduced peripheral resistance and lower blood pressure without affecting bradykinin metabolism, which distinguishes it from ACE inhibitors.
Clinically, Irbesartan is primarily prescribed for treating essential hypertension in adults, helping to reduce the risk of stroke and cardiovascular events. It is also indicated for the treatment of nephropathy in patients with type 2 diabetes and hypertension, as it slows the progression of renal disease by reducing intraglomerular pressure. The drug exhibits high bioavailability, with peak plasma concentrations reached within two to three hours after oral administration. Its long half-life allows for once-daily dosing, ensuring consistent therapeutic effects throughout the day. Common side effects are generally mild and may include dizziness or fatigue, though hypotension can occur, particularly in volume-depleted patients.
Irbesartan is available in various tablet strengths, typically ranging from 75 mg to 300 mg, facilitating flexible dosage adjustments based on individual patient needs. Extensive clinical trials have demonstrated its efficacy and safety profile over long-term use, making it a first-line therapy in many international guidelines. As a member of the tetrazole class of ARBs, it offers a favorable pharmacokinetic profile with minimal drug-drug interactions compared to other antihypertensive agents. This makes it an ideal choice for patients with complex comorbidities requiring stable blood pressure control and organ protection.